Back to search

Peptide record

TPDB41338

HR Anticancer standard
8 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41338
HR
Anticancer
Cancer-related peptides
CancerPPD 2.0 Peptipedia
standard
No
A 8-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0 and Peptipedia, with an available 3D structural model.
Sequence
HVLSRAPR
Physicochemical Analysis
C40H70N16O10
NDCEQGIKMFTWY
R
935.10
12.40
3
0
3
+2
2.50
-0.600
97.50
Mammalian: 3.5 hour Yeast: 10 min E.coli: >10 hour
0
0.00
1
Residue Composition
number
1
A
2
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
0
I
1
L
0
K
0
M
0
F
1
P
1
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 1 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 0 L: 1 K: 0 M: 0 F: 0 P: 1 S: 1 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
8
C40H70N16O10
935.10
12.40
+2
2.50
-0.600
Free
L
Linear
Free
Anticancer
Fraction identified from Tr1
Evidence Records 4 records
Evidence 1 Activity

Activity

IC50
IC50 = 99.88 µg/mL
Anticancer
99.88 µg/mL

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2017

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

22% inhibition at 500 µg/mL
Anticancer

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2017
Evidence 3 Activity

Activity

20% inhibition at 500 µg/mL
Anticancer

Target

Gastric Cancer
SGC-7901
Stomach

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2017
Evidence 4 Activity

Activity

15% inhibition at 500 µg/mL
Anticancer

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2017